Haemonetics Corporation (HAE) : American Capital Management Inc reduced its stake in Haemonetics Corporation by 12.86% during the most recent quarter end. The investment management company now holds a total of 609,386 shares of Haemonetics Corporation which is valued at $20,877,564 after selling 89,930 shares in Haemonetics Corporation , the firm said in a disclosure report filed with the SEC on Aug 3, 2016.Haemonetics Corporation makes up approximately 1.67% of American Capital Management Inc’s portfolio.
Other Hedge Funds, Including , California Public Employees Retirement System boosted its stake in HAE in the latest quarter, The investment management firm added 4,200 additional shares and now holds a total of 102,700 shares of Haemonetics Corporation which is valued at $3,518,502. Haemonetics Corporation makes up approx 0.01% of California Public Employees Retirement System’s portfolio.Ls Investment Advisors boosted its stake in HAE in the latest quarter, The investment management firm added 174 additional shares and now holds a total of 2,148 shares of Haemonetics Corporation which is valued at $63,516.Van Berkom Associates boosted its stake in HAE in the latest quarter, The investment management firm added 224,655 additional shares and now holds a total of 1,526,725 shares of Haemonetics Corporation which is valued at $45,145,258. Haemonetics Corporation makes up approx 1.97% of Van Berkom Associates’s portfolio. Quotient Investors added HAE to its portfolio by purchasing 22,800 company shares during the most recent quarter which is valued at $693,576. Haemonetics Corporation makes up approx 0.32% of Quotient Investors’s portfolio.
Haemonetics Corporation closed down -0.06 points or -0.17% at $35.35 with 3,55,736 shares getting traded on Monday. Post opening the session at $35.41, the shares hit an intraday low of $35.09 and an intraday high of $35.67 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
On the company’s financial health, Haemonetics Corporation reported $0.25 EPS for the quarter, missing the analyst consensus estimate by $ -0.04 based on the information available during the earnings call on Aug 1, 2016. Analyst had a consensus of $0.29. The company had revenue of $210.00 million for the quarter, compared to analysts expectations of $205.41 million. The company’s revenue was down -1.6 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.35 EPS.
Many Wall Street Analysts have commented on Haemonetics Corporation. Company shares were Reiterated by Jefferies on Aug 2, 2016 to “Buy”, Firm has raised the Price Target to $ 40 from a previous price target of $32 .Company shares were Reiterated by The Benchmark Company on Aug 2, 2016 to “Hold”, Firm has raised the Price Target to $ 32 from a previous price target of $28 .Haemonetics Corporation was Upgraded by Goldman to ” Neutral” on May 16, 2016.
Haemonetics Corporation is a healthcare company which provides blood management solutions to its customers. The Company’s portfolio of integrated devices information management and consulting services offers blood management solutions for each facet of the blood supply chain. It serves three customer segments: manufacturers of plasma derived pharmaceuticals blood collectors and hospitals. Its multiple product lines under four global product categories include Plasma Blood Center Hospital and Software Solutions. Its Plasma includes plasma collection devices and disposables. Its Blood Center includes blood collection and processing devices and disposables. Its Hospital includes surgical blood salvage and blood demand diagnostic devices and disposables. Its Software Solutions includes information technology platforms and consulting services provided to all three markets. It operates in North America Plasma North America Blood Center and Hospital Europe Asia Pacific and Japan.